Biogen Gets Temporary Halt On Unapproved Mylan MS Drug
Biogen has urged the Federal Circuit to bar Mylan from moving forward with a generic version of Biogen's top-selling multiple sclerosis drug Tecfidera while it appeals a patent invalidation, leading the...To view the full article, register now.
Already a subscriber? Click here to view full article